Established Cardiovascular Disease: Pediatric vs. Adult Differences

Established cardiovascular disease in children is overwhelmingly structural and genetic, congenital heart defects, inherited cardiomyopathies, and coronary damage from Kawasaki disease, while established cardiovascular disease in adults is overwhelmingly acquired, driven by atherosclerotic plaque that accumulates over decades. That distinction is what determines which test comes first (echocardiography in a child, coronary imaging or catheterization in an adult), which drug classes have a pediatric evidence base at all, and how often a patient needs follow-up. Adults who were born with congenital heart disease sit in between: their anatomy is pediatric in origin, but their complications over time increasingly resemble adult acquired heart disease.

What counts as "established" cardiovascular disease at each age

In adults, established CVD is generally defined by a documented event or confirmed disease burden: prior myocardial infarction, coronary revascularization, ischemic stroke, peripheral artery disease, or atherosclerotic plaque confirmed on imaging. In children, "established" more often means a confirmed anatomic or genetic diagnosis: a congenital heart defect identified on echocardiogram, an inherited cardiomyopathy, coronary artery aneurysms from Kawasaki disease, or rheumatic valve damage.

This difference matters clinically. Applying adult criteria to a child risks missing disease that is present but silent, for example, a teenager with familial hypercholesterolemia whose LDL cholesterol has already been elevated for years, well before any adult-style event occurs. Autopsy and cohort research going back decades (the Bogalusa Heart Study and related work) has shown that early atherosclerotic changes can be present in childhood and adolescence, correlating with cholesterol levels earlier in life, though the exact magnitude of lesion burden at specific ages varies across studies and should be checked against the primary literature rather than quoted as a fixed number.

A shared biological thread

Despite different dominant causes, inflammation and endothelial dysfunction contribute to disease progression in both age groups. Pediatric cardiology increasingly studies markers of vascular risk in children with congenital heart disease and in children with obesity, and a growing body of work links pediatric sleep-disordered breathing, particularly obstructive sleep apnea, to early cardiovascular risk phenotypes such as elevated blood pressure and vascular stiffness (evidence review). This is an active research area rather than a settled clinical rule, and it does not establish that treating pediatric OSA reverses cardiovascular risk; it establishes that the association is worth watching in a child with both conditions.

Etiology: structural and genetic disease vs. acquired atherosclerosis

Congenital heart disease is the pediatric prototype. U.S. surveillance data commonly cited by the CDC puts the frequency of congenital heart defects at roughly 8 per 1,000 live births, with ventricular septal defect as the most frequently diagnosed isolated lesion (see the CDC congenital heart defects data page, current as of the date noted on that page). Genetic syndromes explain a meaningful share of congenital heart disease: Down syndrome (trisomy 21) is well established as carrying a substantially elevated rate of congenital cardiac defects, most often an atrioventricular septal defect, and Turner syndrome is associated with bicuspid aortic valve and coarctation of the aorta. Exact percentage estimates for these associations vary by cohort and should be verified against a current pediatric cardiology or genetics reference before being used in a specific clinical discussion.

Atherosclerosis is the adult prototype. It begins asymptomatically, often in the second or third decade of life, and by the time a person in their fifties presents with an acute coronary event, the underlying plaque has typically been developing for many years. Older autopsy-based research (including the PDAY study) documented early atherosclerotic lesions in adolescents and young adults, but specific lesion-prevalence percentages by age band from that era of research should be confirmed against the original publication before being cited as current fact, since this draft could not verify a live, working citation for those figures.

Kawasaki disease is a pediatric cause of acquired coronary artery disease. It is a self-limited vasculitis, most common in children under age five, that can cause coronary artery aneurysms if untreated. Timely treatment with intravenous immunoglobulin substantially reduces aneurysm risk compared with no treatment; the exact untreated-versus-treated percentages commonly quoted in review articles should be checked against the current American Heart Association scientific statement on Kawasaki disease before being used as a precise clinical figure. Adults who had Kawasaki disease as children are an increasingly recognized subgroup with coronary disease that can look like atherosclerotic disease on angiography but has a different origin.

How the two groups present

Children with established CVD rarely present with classic chest pain. Neonates with critical congenital heart disease present with cyanosis, respiratory distress, or poor feeding, often in the first days of life as the ductus arteriosus closes. Older children with cardiomyopathy may present with exercise intolerance, unexplained syncope, or a murmur found incidentally. In some inherited cardiomyopathies, sudden cardiac events can be the first sign of disease in a previously asymptomatic adolescent, which is the clinical rationale for screening first-degree relatives when a pediatric cardiomyopathy diagnosis is made.

Adults with established atherosclerotic CVD present across a spectrum from asymptomatic disease found incidentally on imaging to acute coronary syndrome. Angina is the most familiar symptomatic presentation, but atypical presentations, nausea, jaw pain, unexplained fatigue, are more common in women and in people with diabetes, and can delay recognition of an evolving heart attack.

When either presentation is urgent: a child with cyanosis, poor feeding and rapid breathing in the first weeks of life, or an adolescent with exertional syncope in the setting of a family history of cardiomyopathy or sudden death, needs urgent cardiology evaluation. An adult with chest pressure, exertional dyspnea, or classic or atypical anginal symptoms in the setting of known risk factors should not defer evaluation. Neither of these situations is appropriate for self-directed management.

Diagnostics: different first-line tools for different diseases

Pediatric cardiology relies on echocardiography as the default first test for almost any suspected structural or functional heart problem, because it defines anatomy and quantifies chamber size and function without radiation, and because pediatric echocardiographic normal ranges are indexed to body size rather than fixed adult cutoffs (a chamber dimension that is normal in an adult may be markedly abnormal in a young child).

Adult cardiology relies more heavily on electrocardiography, stress testing, coronary CT angiography, and invasive catheterization, and increasingly uses coronary artery calcium scoring to refine risk in adults who are otherwise at intermediate risk. Coronary calcium scoring is not part of routine pediatric evaluation because calcified plaque is rare before adulthood outside of extreme phenotypes such as homozygous familial hypercholesterolemia.

Genetic testing has a larger and more routine role in pediatric cardiology than in general adult cardiology: it is standard practice to test for known cardiomyopathy and long-QT genes when a pediatric diagnosis is made, both to guide the individual patient's care and to screen relatives. In adults, genetic testing is used selectively, most often when familial hypercholesterolemia or an inherited arrhythmia syndrome is suspected.

Treatment differences: what has pediatric evidence and what does not

This is the area where pediatric and adult cardiology diverge most sharply in terms of evidence quality, and it is important to state plainly: many pediatric cardiovascular drug regimens are extrapolated from adult trial data and adjusted for weight, not established through dedicated large pediatric randomized trials.

Statins. High-intensity statin therapy is a well-established guideline recommendation for adults with established atherosclerotic CVD, supported by a large body of trial evidence linking LDL cholesterol lowering to reduced cardiovascular events. In children with heterozygous familial hypercholesterolemia, professional guidelines support statin initiation starting around age 8 to 10 under specialist supervision, with routine monitoring during dose adjustment. This is a guideline-based pediatric recommendation, not an adult indication simply lowered in age; the pediatric trial base is smaller than the adult base, and treatment decisions in an individual child should be made by a pediatric lipid specialist.

Antiplatelet and anticoagulant therapy. Aspirin and, after acute coronary syndrome or stenting, dual antiplatelet therapy are standard adult treatments supported by large trials. In children, aspirin is used mainly in the acute and convalescent phases of Kawasaki disease and in children with mechanical valves or certain shunts. Newer antiplatelet agents used routinely in adults (such as ticagrelor) have a much thinner pediatric pharmacokinetic evidence base, and their use in children is specialist-directed rather than standardized.

Beta-blockers and renin-angiotensin system inhibitors. These are guideline-directed therapy after adult myocardial infarction and in adult heart failure, supported by landmark trials from the 1990s onward (for example, the SAVE trial's finding that an ACE inhibitor reduced cardiovascular mortality after anterior myocardial infarction). Children with dilated cardiomyopathy are often treated with the same drug classes, but pediatric heart failure trials have generally been small, and a Cochrane review of beta-blockers in pediatric heart failure found a trend toward improved ventricular function without being large enough to confirm a mortality benefit. This is a genuine evidence gap, not a minor caveat, and it should be described to families as such.

Newer agents (PCSK9 inhibitors, SGLT2 inhibitors). Evolocumab, alirocumab, and SGLT2 inhibitors such as empagliflozin and dapagliflozin have adult trial evidence supporting reductions in LDL cholesterol, cardiovascular death, or heart failure events in specific adult populations. As of early 2025, none of these drug classes carry FDA approval for established cardiovascular disease in pediatric populations; pediatric use, where it occurs, is investigational or reserved for rare severe phenotypes such as homozygous familial hypercholesterolemia, under specialist care. This status can change, and it should be verified against the current FDA label before being repeated as a fixed fact.

Surgery and catheter-based procedures

Surgery and catheter intervention are frequently the primary treatment in pediatric established CVD, while in adults pharmacotherapy is usually tried first, with revascularization reserved for specific anatomic or symptomatic thresholds.

Neonates with critical congenital heart disease (for example, transposition of the great arteries) undergo corrective surgery, often within the first weeks of life, at specialized pediatric cardiac surgery centers. Neonatal cardiac surgery uses different physiology than adult surgery, including deep hypothermic circulatory arrest in some repairs, reflecting the different tolerances of an immature brain and cardiovascular system.

In adults with stable ischemic heart disease, percutaneous coronary intervention relieves angina but has not been shown in large contemporary trials (such as ISCHEMIA) to reduce mortality compared with optimal medical therapy alone in stable disease. In ST-elevation myocardial infarction, however, prompt primary PCI is the standard of care and is associated with better outcomes than delayed treatment. Transcatheter aortic valve replacement has become a standard option for older adults with severe aortic stenosis across a range of surgical risk levels, based on multiple randomized trials; none of this applies to pediatric structural valve disease, which is managed with different techniques.

Adult congenital heart disease: the bridge population

A large and growing number of adults are now living with congenital heart disease that would have been fatal in infancy a few decades ago. This population is often referred to using the shorthand "ACHD." Their anatomy is congenital, but many of their complications over time, arrhythmia, heart failure, pulmonary hypertension, valve dysfunction, endocarditis risk, resemble adult acquired heart disease. Professional guidelines recommend that adults with moderate-to-complex congenital heart disease be followed at a specialized ACHD center, with the required frequency depending on anatomic complexity.

Comparison: matching the patient to the pathway

This table is a general orientation framework, not a diagnostic or treatment algorithm for an individual patient. Actual management decisions depend on the specific lesion, genetic diagnosis, comorbidities, and specialist assessment.

Risk factor management across the lifespan

Pediatric guidelines support universal lipid screening in childhood and again in adolescence, and define pediatric hypertension using age-, sex-, and height-adjusted percentile tables rather than the fixed adult blood pressure threshold. This is a structural difference, not a simplification: a blood pressure reading that is normal by adult standards can be hypertensive for a young child.

Adults with established CVD are generally managed toward guideline-based LDL cholesterol targets (commonly below 70 mg/dL, and lower in very-high-risk patients under some guideline versions), blood pressure below 130/80 mmHg, smoking cessation, and regular physical activity. Exact numeric thresholds are periodically revised by professional societies, so a clinician's current guideline version should be checked rather than assuming these numbers are unchanged from any single year's publication.

Prognosis and long-term outcomes

Children with repaired congenital heart disease have far better survival than historical cohorts, but repair is not a cure in the sense of returning to baseline lifelong risk. Many patients carry a lifelong residual risk of arrhythmia, ventricular dysfunction, or the need for reoperation, which is why structured lifelong follow-up, not a single successful surgery, defines good long-term care in this population.

Adults with established atherosclerotic CVD who reach guideline-directed treatment targets tend to have substantially lower rates of recurrent cardiovascular events than those who do not, and outcomes after events like ST-elevation myocardial infarction have improved over recent decades with faster reperfusion protocols and modern antiplatelet therapy. Precise event-rate percentages change as registries update; a clinician discussing individual prognosis should use current registry or guideline data rather than a fixed historical figure.

What is established, what is plausible, and what is not established

Established: Pediatric and adult cardiovascular disease have different dominant causes (structural/genetic versus acquired atherosclerotic), different first-line diagnostic tools, and different depths of drug trial evidence. Congenital heart disease is a recognized and reasonably common birth condition tracked by public health surveillance. Kawasaki disease can cause coronary artery aneurysms, and timely immunoglobulin treatment reduces that risk. Adults living with congenital heart disease are a real and growing clinical population requiring specialized, ongoing follow-up.

Plausible but not fully settled: The degree to which pediatric inflammatory or metabolic markers (including sleep-disordered breathing) predict adult cardiovascular outcomes is an active research area rather than a proven causal pathway with an established clinical intervention. The exact numeric thresholds and percentages historically cited for early atherosclerosis prevalence by age band come from older cohort and autopsy studies whose precise figures should be checked against the primary literature before being used in patient-facing material.

Not established: PCSK9 inhibitors and SGLT2 inhibitors do not have FDA approval for established cardiovascular disease in pediatric populations as of early 2025, and this status should be reverified before citing it as current. This article does not establish individualized dosing, does not replace pediatric or adult cardiology consultation, and does not substitute for emergency evaluation when red-flag symptoms are present.